PRDS

Pardes Biosciences, Inc. [PRDS] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

PRDS Stock Summary

In the News

PRDS Financial details

Company Rating
-
Market Cap
135.19M
Income
-96.28M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
57
Optionable
No
Shortable
Yes
Earnings
06 Nov 2023
P/E
-1.36
Forward P/E
-
PEG
0.16
P/S
-
P/B
0.84
P/C
-
P/FCF
-1.72
Quick Ratio
79.58
Current Ratio
81.72
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.63
EPS next Y
-
EPS next Q
-
EPS this Y
-84.12%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-25%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-61%
ROE
-55%
ROC
-0.54%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.75-3.67
52W High
-
52W Low
-
RSI
-
Rel Volume
4.22
Avg Volume
509.69K
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
0.423296
-
-
Volatility
0.01%, 0.01%
Prev Close
-
Price
-
Change
-

Something similar

Top by Market Cap
TL0.DE
BRYN.DE
V
GOOGL
VTSAX
Same Sector
603387.SS
POLN.SW
BEAM
MLC.IR
NXTC
Check Those
USI
SAII
2331.T
002546.SZ
3141.T
Similar Market Cap
DXB.TO
JLS
CAT31.PA
ERESU
PUI

Company Profile

Healthcare Biotechnology
  • Volume Average 509.69K
  • Market Capitalization 135.19M
  • Employee 57
  • CEO Mr. Thomas G. Wiggans
  • Headquarters Carlsbad,CA,US
  • IPO Date 2021-12-27
  • Website https://www.pardesbio.com

Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome coronavirus 2 infections and associated diseases. The company was incorporated in 2020 and is headquartered in Carlsbad, California.